Citius Oncology (NASDAQ:CTOR) Now Covered by Analysts at Maxim Group

Maxim Group assumed coverage on shares of Citius Oncology (NASDAQ:CTOR) in a research note published on Wednesday, MarketBeat reports. The brokerage issued a buy rating and a $3.00 price target on the stock.

Citius Oncology Price Performance

Citius Oncology stock opened at $0.92 on Wednesday. Citius Oncology has a 52-week low of $0.85 and a 52-week high of $49.00. The stock’s 50 day moving average price is $1.16.

About Citius Oncology

TenX Keane Acquisition Corp. is a blank check company. It formed for the purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. TenX Keane Acquisition Corp. is based in New York.